Stockscreener 앱 받기
8.82
5.82%
-0.545
시간 외 거래:
8.92
0.10
+1.13%
전일 마감가:
$9.365
열려 있는:
$9.23
하루 거래량:
1.77M
Relative Volume:
0.84
시가총액:
$937.92M
수익:
$139.71M
순이익/손실:
$-209.36M
주가수익비율:
-2.9797
EPS:
-2.96
순현금흐름:
$-160.60M
1주 성능:
-4.34%
1개월 성능:
-16.32%
6개월 성능:
-33.28%
1년 성능:
-59.03%
1일 변동 폭
$8.775
$9.40
1주일 범위
$8.74
$9.561
52주 변동 폭
$8.58
$25.07
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
명칭
Syndax Pharmaceuticals Inc
전화
781-419-1400
주소
730 THIRD AVENUE, NEW YORK, MA
SNDX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
8.82 | 937.92M | 139.71M | -209.36M | -160.60M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-06-28 | 개시 | Jefferies | Buy |
| 2024-01-31 | 다운그레이드 | Scotiabank | Sector Outperform → Sector Perform |
| 2023-12-22 | 개시 | Mizuho | Buy |
| 2023-10-25 | 개시 | BofA Securities | Buy |
| 2023-10-11 | 개시 | Goldman | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Outperform |
| 2023-07-11 | 개시 | Guggenheim | Buy |
| 2023-04-17 | 재개 | BTIG Research | Buy |
| 2023-01-31 | 개시 | Stifel | Buy |
| 2023-01-03 | 개시 | JP Morgan | Overweight |
| 2022-07-28 | 재개 | B. Riley Securities | Buy |
| 2022-04-11 | 개시 | H.C. Wainwright | Buy |
| 2022-02-15 | 개시 | Goldman | Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-05-25 | 개시 | Citigroup | Buy |
| 2021-02-18 | 개시 | B. Riley Securities | Buy |
| 2020-12-03 | 개시 | Stifel | Buy |
| 2020-05-22 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-05-22 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-05-18 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-05-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-13 | 재확인 | H.C. Wainwright | Buy |
| 2019-03-08 | 재확인 | H.C. Wainwright | Buy |
| 2019-01-04 | 개시 | Robert W. Baird | Outperform |
| 2018-01-05 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-03-16 | 개시 | FBR & Co. | Outperform |
| 2017-03-02 | 개시 | Instinet | Buy |
| 2016-10-07 | 개시 | Guggenheim | Buy |
| 2016-03-28 | 개시 | Citigroup | Buy |
| 2016-03-28 | 개시 | JMP Securities | Mkt Outperform |
| 2016-03-28 | 개시 | Morgan Stanley | Overweight |
모두보기
Syndax Pharmaceuticals Inc 주식(SNDX)의 최신 뉴스
Learn to Evaluate (SNDX) using the Charts - news.stocktradersdaily.com
Syndax Pharmaceuticals’ SWOT analysis: revuforj launch boosts aml treatment stock - Investing.com
Syndax Pharmaceuticals' SWOT analysis: revuforj launch boosts aml treatment stock - Investing.com
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Down 3.7%What's Next? - MarketBeat
Assenagon Asset Management S.A. Lowers Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax reports publication of revumenib data from BEAT AML trial - Yahoo Finance
SNDX Trial Data Shows Promising Results in AML Treatment | SNDX Stock News - GuruFocus
Syndax Presents New Revuforj® (revumenib) Data in - GlobeNewswire
Syndax Announces Publication of Revumenib Data from the BEAT AML - GuruFocus
Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025 - The Manila Times
Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025 | SNDX Stock News - GuruFocus
Syndax Announces Publication of Revumenib Data from the - GlobeNewswire
Clinical Trial: New AML Drug Achieves 100% MRD Negativity, Doubles Survival vs Standard Care - Stock Titan
Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of ... - Eagle-Tribune
Syndax Pharma releases new data from its AUGMENT-101 trial of Revuforj - The Pharma Letter
Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refra - GuruFocus
SNDX: New Data Revealed from Syndax's AUGMENT-101 Trial | SNDX Stock News - GuruFocus
Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025 | SNDX Stock News - GuruFocus
Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025 - The Manila Times
Syndax Pharmaceuticals at Goldman Sachs Conference: Strategic Growth and Profitability - Investing.com Canada
Transcript : Syndax Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 02 - MarketScreener
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 32,653 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Ameriprise Financial Inc. - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Wall Street Analysts See a 219.98% Upside in Syndax (SNDX): Can the Stock Really Move This High? - MSN
Syndax Pharmaceuticals at Jefferies Conference: Strategic Growth and Expansion By Investing.com - Investing.com Canada
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Li - GuruFocus
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | SNDX Stock News - GuruFocus
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Ameriprise Financial Inc. Has $423,000 Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World
Bank of America Corp DE Sells 546,799 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Long Term Trading Analysis for (SNDX) - news.stocktradersdaily.com
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Nuveen Asset Management LLC - MarketBeat
Voloridge Investment Management LLC Acquires Shares of 79,071 Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Wellington Management Group LLP Has $55.98 Million Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Trading 4.9% HigherShould You Buy? - MarketBeat
84,998 Shares in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Purchased by Polar Asset Management Partners Inc. - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Bank of America Corp DE - Defense World
Millennium Management LLC Lowers Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Brokerages Set Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Target Price at $35.91 - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Two Sigma Investments LP - MarketBeat
Syndax Announces Participation in June Investor Conferences | SN - GuruFocus
Syndax Announces Participation in June Investor Conferences - The Manila Times
Syndax Pharmaceuticals Inc (SNDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Syndax Pharmaceuticals Inc 주식 (SNDX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Huber Martin H. Jr. | Director |
May 19 '25 |
Buy |
8.99 |
5,000 |
44,950 |
79,000 |
| Katkin Keith | Director |
May 19 '25 |
Buy |
9.11 |
10,000 |
91,120 |
100,000 |
| Metzger Michael A | Chief Executive Officer |
Mar 14 '25 |
Option Exercise |
7.20 |
6,074 |
43,733 |
306,195 |
| Metzger Michael A | Chief Executive Officer |
Mar 04 '25 |
Option Exercise |
7.20 |
7,814 |
56,261 |
307,935 |
| Metzger Michael A | Chief Executive Officer |
Mar 04 '25 |
Sale |
15.05 |
7,814 |
117,564 |
300,121 |
0.39%
0.42%
자본화:
|
볼륨(24시간):